Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

Completion of 5-year adjuvant endocrine therapy in the community

Authors: B Makubate, AM Thompson, JA Dewar, C McCowan

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

Adjuvant endocrine therapy is recommended for all eligible patients with breast cancer for a minimum 5-year period. Durations of therapy for a shorter period have worse outcomes for patients. This study examined whether women in the community completed the full course of adjuvant endocrine therapy. …
Metadata
Title
Completion of 5-year adjuvant endocrine therapy in the community
Authors
B Makubate
AM Thompson
JA Dewar
C McCowan
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2551

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Poster presentation

Radiotherapy fraction size sensitivity is modulated by DNA repair systems

Poster presentation

Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer

Poster presentation

Macrophage-mediated breast cancer cell chemotaxis: the role of sphingosine kinase-1 activation

Poster presentation

Anti-HER2 imaging agents for breast cancer imaging

Poster presentation

Opticin: a potent anti-angiogenic/antiproliferative agent for breast cancer therapy

Poster presentation

An integrated informatics platform to facilitate transforming tissue into knowledge
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits